Literature DB >> 16691425

Nonhypotensive dose of beta-adrenergic blocker ameliorates capillary deficits in the hearts of rats with moderate renal failure.

Kerstin Amann1, Jürgen Hofstetter, Valentina Câmpean, Andreas Koch, Marie-Luise Gross, Roland Veelken, Eberhard Ritz.   

Abstract

Renal failure causes sympathetic overactivity and inadequate capillary growth in response to cardiomyocyte hypertrophy in experimental renal failure, as well as in uremic patients. In nonuremic animals, sympathetic overactivity was shown to suppress capillary growth. The purpose of this study was to examine whether blockade with alpha- and beta-adrenoblockers ameliorates the capillary deficit that was documented in the hearts of rats with moderate renal failure. Male Sprague-Dawley rats, 3 days after surgical ablation [subtotal nephrectomy (SNX)] or sham operation (sham), were treated with phenoxybenzamine, metoprolol, or a combination of both: After 12 weeks, the hearts were investigated using morphometric and stereologic techniques. The length density of myocardial capillaries was lower (p<0.05) in untreated SNX than in sham (2,786+/-372 vs 3,397+/-602 mm/mm3); the decrease was abrogated by metoprolol (3,305+/-624 mm/mm3), but not by phenoxybenzamin (2,628+/-480 mm/mm3). The intercapillary distance increased (p<0.05) in SNX (20.5+/-1.5 microm) and tended to be lower after metoprolol treatment (19.0+/-1.9 microm). The media area of intramyocardial arterioles was significantly higher in untreated SNX (1,158+/-1,343 vs 686+/-771 microm2 in sham). Metoprolol in nonhypotensive doses prevents the capillary deficit in the hearts of rats with moderate renal failure and presents an argument for an important role of sympathetic overactivity in the genesis of the capillary deficit in moderate chronic renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16691425     DOI: 10.1007/s00428-006-0219-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  45 in total

Review 1.  Epidemiology of cardiovascular disease in chronic renal disease.

Authors:  R N Foley; P S Parfrey; M J Sarnak
Journal:  J Am Soc Nephrol       Date:  1998-12       Impact factor: 10.121

2.  Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.

Authors:  G Ligtenberg; P J Blankestijn; P L Oey; I H Klein; L T Dijkhorst-Oei; F Boomsma; G H Wieneke; A C van Huffelen; H A Koomans
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

3.  Remodeling of resistance arteries in renal failure: effect of endothelin receptor blockade.

Authors:  Kerstin Amann; Gabriel Mil Tenberger-Mil Tenyi; Aurelia Simonoviciene; Andreas Koch; Stephan Orth; Eberhard Ritz
Journal:  J Am Soc Nephrol       Date:  2001-10       Impact factor: 10.121

4.  Reduced chronotropic responsiveness of the heart in experimental uremia.

Authors:  J F Mann; K H Jakobs; J Riedel; E Ritz
Journal:  Am J Physiol       Date:  1986-05

5.  Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity.

Authors:  Shaohua Ye; Huiqin Zhong; Vijay Yanamadala; Vito M Campese
Journal:  Am J Hypertens       Date:  2002-08       Impact factor: 2.689

6.  Myocyte/capillary mismatch in the heart of uremic patients.

Authors:  K Amann; M Breitbach; E Ritz; G Mall
Journal:  J Am Soc Nephrol       Date:  1998-06       Impact factor: 10.121

7.  Systolic hypertension in hemodialysis patients.

Authors:  Rajiv Agarwal
Journal:  Semin Dial       Date:  2003 May-Jun       Impact factor: 3.455

8.  Role of sympathetic nerves during developing cardiac hypertrophy in Grollman hypertensive rats.

Authors:  R J Tomanek; D W Carlson; P J Palmer; R K Bhatnagar
Journal:  Am J Physiol       Date:  1987-10

9.  Sympathectomy stimulates capillary but not precapillary growth in hypertrophic hearts.

Authors:  R J Torry; P M Connell; D M O'Brien; W M Chilian; R J Tomanek
Journal:  Am J Physiol       Date:  1991-05

10.  A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia.

Authors:  K Amann; E Ritz; G Wiest; G Klaus; G Mall
Journal:  J Am Soc Nephrol       Date:  1994-04       Impact factor: 10.121

View more
  4 in total

Review 1.  Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.

Authors:  David Charytan
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

2.  Capillaries as a Therapeutic Target for Heart Failure.

Authors:  Yohko Yoshida; Ippei Shimizu; Tohru Minamino
Journal:  J Atheroscler Thromb       Date:  2022-04-01       Impact factor: 4.394

Review 3.  Do beta-blockers combined with RAS inhibitors make sense after all to protect against renal injury?

Authors:  Eberhard Ritz; Lars Christian Rump
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

Review 4.  Vascular Calcification in Chronic Kidney Disease: The Role of Inflammation.

Authors:  Kerstin Benz; Karl-Friedrich Hilgers; Christoph Daniel; Kerstin Amann
Journal:  Int J Nephrol       Date:  2018-08-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.